1999 Milestones And Equity Investments From Corporate Partners (Ongoing Alliances)

Company Partner Amt. (M) Triggering Event Details/Date
Advanced Tissue Sciences Inc. Smith & Nephew plc (UK) 15 Terms of agreement to expand Dermagraft joint venture The companies signed a joint venture in 4/96 on Advanced Tissue's Dermagraft for treating diabetic foot ulcers, and expanded it in 1/98 to include indications of venous and pressure ulcers as well as the product TransCyte (formerly Dermagraft-TC) for treating burns, outside the U.S.; this was expanded in 8/98 to include marketing of TransCyte in the U.S.; Advanced Tissue received a $15M payment in conjunction with the agreement (1/4)
Alkermes Inc. Genentech Inc. 35 Expansion of agreement for Nutropin Depot, injectable, sustainedrelease formulation of human growth hormone Genentech purchased $35M in convertible, exchangeable preferred Alkermes stock with a conversion price of at least $45 per share; Alkermes has the option to redeem preferred stock in cash or common stock at any time (4/15)
AntexBiologics Inc. Pasteur Merieux Connaught (unit of Rhone-Poulenc Group; France) 0.5 Clinical development milestone The companies signed a licensing agreement in 12/94 on Antex's recombinant Haemophilus influenzae (nontypeable) vaccine for treating inner ear infections (otitis media) in infants and children and upper respiratory disorders in the elderly; Antex received a $0.5M clinical development milestone (triggering event not identified) (1/20)
Ariad Pharmaceuticals Inc. Hoechst Marion Roussel Inc. (subsidiary of Hoechst AG; Germany) 5.7 Terms of agreement on joint venture The companies formed a joint venture, the Hoechst-Ariad Genomics Center LLC, in 3/97 in functional genomics; under terms of the agreement, Ariad had the option, beginning in 1999, to issue $25M in Series B preferred stock to Hoechst Marion over the remaining term; in this 1st tranche of that option, Ariad issued 478,120 shares to Hoechst Marion for proceeds of $5.747M (1/7)
Ariad Pharmaceuticals Inc. Hoechst Marion Roussel Inc. (subsidiary of Hoechst AG; Germany) 2 Achievement of 2nd milestone The companies entered an agreement in 11/95 to develop small-molecule drugs that block the activity of the Src protein for treating osteoporosis and other bone diseases; Ariad achieved the 2nd milestone (undisclosed) in the collaboration, triggering the payment (2/16)
Aronex Pharmaceuticals Inc. Abbott Laboratories 5.6 Completion of Phase III trials in U.S. and Europe The companies signed a licensing agreement in 11/98 on Aronex's Nyotran (liposomal formulation of Nystatin) for treating systemic fungal infections; Aronex completed patient enrollment and treatment in Phase III trials in the U.S. and Europe, triggering 2 milestone payments (totaling $5.6M) from Abbott (1/11)
Aronex Pharmaceuticals Inc. Abbott Laboratories 6.3 Milestone related to clinical development of Nyotran (injectable formulation of nystatin) Abbott made $6.3M payment for achievement of milestone related to Nyotran development (4/13)
Avant Immunotherapeutics Inc. Heska Corp. ND Achievement of development milestone Avant received an undisclosed milestone payment from Heska Corp. for achieving a milestone in efforts to develop and utilize Avant's PCPP polymer as an adjuvant in Heska's animal health vaccine against B. henselae, the bacterium that causes Cat Scratch Disease in people (9/9)
BioCryst Pharmaceuticals Inc. Ortho-McNeil Pharmaceutical Inc. unit of Johnson & Johnson 2 Initiation of Phase II trial Ortho-McNeil paid BioCryst $2M milestone for starting Phase II trial of oral influenza neuraminidase inhibitor designed to treat and prevent viral influenza; milestone stems from 9/98 agreement (6/23)
BioTime Inc. Abbott Laboratories 0.9 FDA approval of Hextend and the commencement of sales BioTime received $850,000 from Abbott under its exclusive license agreement for Hextend, BioTime's proprietary blood plasma volume expander (8/25)
BioTransplant Inc. Novartis AG (Switzerland) 2.5 Achievement of research milestone BioTransplant received $2.5M from Novartis for achieving a milestone in a research collaboration involving organ transplant technology (9/27)
Cadus Pharmaceutical Corp. SmithKline Beecham plc (UK) 1 Research milestone The companies signed an agreement in 2/97 to collaborate in functional genomics, especially orphan G-protein coupled receptors identified from the human genome; Cadus has identified ligands for these receptors, triggering a $1M milestone payment (1/12)
Cell Genesys Inc. Hoechst Marion Roussel Inc. (subsidiary of Hoechst AG; Germany) 2 European patent on gene activation technology The companies signed a licensing agreement in 2/97 on Cell Genesys' gene-activated erythropoietin (EPO) and a 2nd undisclosed protein; Cell Genesys was granted a European patent on its gene activation technology in 12/98, triggering the milestone payment (2/16)
Cell Genesys Inc. Japan Tobacco Inc. (Japan) 4.5 Completion of Phase I/II trial Cell Genesys received a $4.5M payment following the completion of an initial Phase I/II trial of GVAX lung cancer vaccine (12/10)
Cell Genesys Inc. Japan Tobacco Inc. (Japan) 2.5 Terms of collaboration agreement CellGenesys received a $2.5M payment following the first anniversary of its worldwide collaboration with Japan Tobacco for the development of GVAX cancer vaccine (12/27)
Celtrix Pharmaceuticals Inc. Elan Corp. plc (Ireland) 15.3 Formation of joint venture plus independent equity investment Elan will purchase up to $12.8M worth of Celtrix preferred stock for $2.006 per share, with proceeds earmarked to fund Celtrix's share of companies' joint venture to treat osteoporosis using SomatoKine (IGF-BP3 complex); separately, Elan bought $2.5M worth of Celtrix common stock at a premium to market (4/13)
Cerus Corp. Baxter Healthcare Corp. 2 Set parameters for Phase III trial of pathogen inactivation system for platelets The companies entered into an agreement in 12/93 to develop and market Cerus' platelet pathogen inactivation system; Cerus and the FDA agreed on the preliminary protocol for U.S. Phase III trials, triggering a $2M stock purchase (at 120% of market) by Baxter (1/26)
CombiChem Inc. Teijin Ltd. (Japan) ND Research milestone CombiChem achieved a research milestone in the evolution and optimization of a series of novel receptor antagonists with in vivo efficacy in animal models of inflammatory disease; financial details ND (11/5)
Connetics Corp. Suntory Pharmaceuticals (Japan) 0.9 Initiation of pivotal trial Suntory paid $0.878M milestone in in connection with Connetics' start of pivotal trial of ConXn (human recombinant relaxin) for the treatment of scleroderma; payment stems from 4/98 agreement for development and commercialization in Japan (5/14)
COR Therapeutics Inc. Schering-Plough Corp. 12 Marketing authorization of Integrilin in the European Union COR received a $12M milestone payment from Schering-Plough in connection with marketing authorization of Integrilin in the European Union for certain indications; Schering will launch and market Integrilin exclusively for a specified period, and COR will receive royalty payments; COR will then have the right to co-promote Integrilin in Europe (8/3)
Corvas International Inc. Schering-Plough Corp. 3 Extension of collaboration agreement Corvas received $3M in funding from Schering-Plough following the extension of their collaboration to develop and commercialize oral anticoagulants based on inhibitors of key protease enzymes in the blood-clotting process (12/14)
Cubist Pharmaceuticals Inc. Merck & Co. ND Achievement of medicinal chemistry research milestone Cubist received a payment from Merck for achieving a milestone under its agreement to develop and commercialize new anti-infective drugs; financial details ND (8/16)
CuraGen Corp. Biogen Inc. and Genentech Inc. 26 Exercise of right under collaborative agreement CuraGen exercised its right under existing collaborative agreements with Biogen and Genentech to borrow an aggregate of $26M; CuraGen converted these loans into approximately 1.6M shares of CuraGen stock at $16.37 per share (10/19)
CV Therapeutics Inc. Biogen Inc. 4.5 Final report on Phase II trial of CVT-124 The companies signed an agreement in 3/97 on CV Therapeutics' CVT-124 (now called Adentri; an adenosine A1-receptor antagonist) for treating edema associated with congestive heart failure; they amended that agreement in 7/98, to accelerate the release of a $4.5M loan to CV Therapeutics (in form of milestone) once Biogen received the final report of an earlier Phase II trial jointly conducted by the partners; the loan is repayable in common stock or cash (1/5)
Cypress Bioscience. Inc Fresenius AG (Germany) 5.2 Exercise of option to acquire manufacturing function and related assets Fresenius exercised option to acquire Prosorba column manu facturing function and related assets located in Redmond, Wash.,as part of marketing agreement (4/27)
Cytoclonal Pharmaceutics Inc. Bristol-Myers Squibb ND Collaborative license and research agreement Cytoclonal received a second payment this year from Bristol-Myers as part of its license and research agreement for the production of paclitaxel; financial details ND (8/20)
Diatide Inc. Nycomed Amersham plc (London) 2 FDA approval of NeoTect Diatide received a $2M milestone payment from Nycomed in connection with FDA approval of NeoTect, Diatide's lung cancer diagnostic imaging product (8/16)
Draxis Health Inc. (Canada) Pfizer Inc. 13 Marketing approval of Anipryl in U.S. and Australia The companies signed a marketing agreement in 11/97 for Draxis' Anipryl (for treating canine Cushing's disease and canine cognitive dysfunction); the FDA approved Anipryl for canine dysfunction on 12/11/98, triggering a $10M milestone; the National Registration Authority in Australia approved the product on 12/14/98 for treating both cognitive dysfunction and Cushing's disease, triggering a $3M milestone payment (1/6)
Epimmune Inc. G.D. Searle & Co. (the pharmaceutical unit of Monsanto Company) 2 Searle's acceptance of a lead product candidate Epimmune received a $2M milestone payment in connection with Searle's acceptance of a lead product candidate for breast, lung and colon cancers, for further preclinical development, IND filing and initial clinical studies; Epimmune will receive an additional milestone payment upon completion of clinical trials (8/27)
Genome Therapeutics Corp. Schering-Plough Corp. ND Achievement of research milestone Genome delivered assays for multiple fungal targets to Schering-Plough related to Candida albicans and Aspergillus fumigatus; financial details ND (10/4)
Genome Therapeutics Corp. Schering-Plough Corp. ND Achievement of collaboration milestone Genome Therapeutics received an undisclosed payment from Schering-Plough related to their alliance to discover new therapeutics for treating asthma (12/20)
Genset (France) Janssen Research Foundation (a subsidiary of Johnson & Johnson) ND Achievemenet of research milestone Genset successfully identified and delivered a novel candidate gene for schizophrenia to Janssen; financial details ND (10/5)
Genzyme Molecular Oncology Schering-Plough Corp. 5 European patent on p53 gene therapy The companies signed a licensing agreement in 10/98 on Genzyme Molecular's rights to p53 gene therapy; a European patent was granted to The Johns Hopkins University (from which Genzyme Molecular had licensed certain diagnostic and therapeutic rights to the p53 gene which it then licensed to Schering-Plough); the granting of the patent triggered a $5M milestone payment (2/4)
Genzyme Tissue Repair Genzyme General 25 Genzyme General's acquisition of GTR's share of NeuroCell joint venture Genzyme General will pay $25M for GTR's 50% stake in NeuroCell, a joint venture between GTR and Diacrin Inc.; of the $25M, $5M is nonrefundable and $20M is a prepayment related to achievement of future milestones; GTR will also receive royalties of 3% on any products (4/1)
Guilford Pharmaceuticals Inc. Rhone-Poulenc Rorer Pharmaceuticals Inc. 2.5 French approval of Gliadel wafer Guilford received a $2.5M milestone payment from Rhone-Poulenc for French approval of the Gliadel wafer as an adjunct to surgery to prolong survival in patients with recurrent glioblastoma multiforme (8/2)
Guilford Pharmaceuticals Inc. Rhone-Poulenc Rorer Pharmaceuticals Inc. 2 German approval of Gliadel wafer Guilford received a $2M milestone payment from Rhone-Poulenc for German approval of the Gliadel wafer as an adjunct to surgery to prolong survival in patients with recurrent glioblastoma multiforme (8/12)
Guilford Pharmaceuticals Inc. Amgen Inc. 5 Achievement of development milestone Guilford received a $5M payment from Amgen for clinical development in their neuroimmunophilin collaboration (12/9)
ICN Pharmaceuticals Inc. Schering-Plough Corp. 27 FDA marketing approval of Rebetron Combination Therapy (ribavirin and recombinant interferon alfa-2b) for hepatitis C Schering-Plough bought 1.1M shares directly from ICN for $24.55 per share on 2/23 in compliance with 7/95 collaboration agreement (4/7)
Icos Corp. Eli Lilly & Co. 15 Initiation of Phase III trial Icos received a $15M milestone payment from Eli Lilly for the initiation of a Phase III trial of IC351, an inhibitor of PDE5, for the treatment of erectile dysfunction (11/3)
ImClone Systems Inc. Merck KGaA (Germany) 5 FDA clearance to start Phase III trial FDA cleared ImClone's Phase III trial of C225 in patients with advanced squamous head and neck cancer (3/9)
ImClone Systems Inc. Merck KGaA (Germany) 3 Initiation of 2nd pivotal trial ImClone received $3M for FDA's approval of 2nd Phase III pivotal trial of anticancer antibody C225 in patients with advanced squamous cell head and neck carcinoma (5/11)
ImClone Systems Inc. American Home Products Corp. 0.5 Filing of investigational new drug application (IND) ImClone received a $0.5M milestone payment from American Home Products upon filing an IND for a vaccine against N. gonorrhea (11/2)
ImClone Systems Inc. Merck KGaA (Germany) 6 Expansion of Phase III trial ImClone received $6M from Merck for the expansion of a Phase III trial of ImClone's C225 cancer therapeutic into Spain (12/2)
The Immune Response Corp. Agouron Pharmaceuticals Inc. 5 Quarterly payment The companies entered an agreement in 6/98 to collaborate on the final development and commercialization of the immune-based therapy Remune for treating HIV infection; this is the 2nd in a series of quarterly payments Agouron will make to Immune Response; it consists of $3M for R&D and $2M for the purchase of 0.15M shares of unregistered common stock (at a premium to market) (1/19)
The Immune Response Corp. Agouron Pharmaceuticals Inc. 5 Clinical milestones The companies entered an agreement in 6/98 to collaborate on the final development and commercialization of the immune-based therapy Remune for treating HIV infection; The Immune Response Corp. received a $5M payment as a result of achieving certain (unidentified) clinical milestones (2/16)
The Immune Response Corp. Agouron Pharmaceuticals Inc. 5 Third of 6 quarterly payments under terms of marketing agreement for Remune HIV therapy The $2M is equity component of $5M quarterly payment, which includes $3M for research; Agouron purchased 0.19M shares of Immune Response at $10.56 per share, a premium to market price (4/20)
The Immune Response Corp. Agouron Pharmaceuticals Inc. (a unit of WarnerLambert Co.) 5 Scheduled payment under terms of development collaboration Immune Response received a $5M payment from Agouron, the fifth of six quarterly payments specified under the terms of the companies' collaboration; the payment consisted of a $3M payment for clinical and manufacturing development expenses, and a $2M payment for the purchase of 0.3M shares of unregistered common stock, purchased at a premium to the market price (10/18)
Immunex Corp. American Home Products Corp. 450 - Immunex issued a 7-year, 3% coupon, convertible subordinated note to AHP in a private placement transaction; note is convertible to common stock at $173.68 per share; full conversion at that price would raise AHP's stake to 55.53% (from 54.11%) (5/20)
ImmunoGen Inc. SmithKline Beecham plc 2 Manufacturing capability ImmunoGen received $2M milestone upon confirmation of company's ability to produce enough huC242-DM1 for clinical trials; milestone stems from 2/99 agreement
ImmunoGen Inc. SmithKline Beecham plc 2.5 Manufacturing capability Upon demonstrating the ability to produce sufficient quantities of huC242-DM1 for clinical trials, ImmunoGen elected to exercise the first of two put options available to it under the terms of its February 1999 license agreement with SmithKline; SB purchased 1M shares of ImmunoGen common stock at $2.44 per share, bringing its total payments to ImmunoGen up to $9.5M (9/27)
Incara Pharmaceuticals Corp. Merck & Co. Inc. 1.5 Achievement of an initial research collaboration milestone Incara received a $1.5M milestone payment from Merck for the achievement of an initial milestone in the company's collaboration targeting the discovery and development of a class of vancomycin analogues; Incara's collaboration with Merck is based on research the company sponsored in the chemistry department of Princeton University; Incara will pay Princeton $0.5M of the milestone payment (8/9)
InSite Vision Inc. Pharmacia & Upjohn 1.5 Completion of Phase II trials InSite received $1.5M from P&U for the completion of Phase II trials evaluating the company's ISV-205 glaucoma treatment; the payment took the form of an equity investment, increasing P&U's ownership of InSite's common shares to just below 10% (9/8)
Interneuron Pharmaceuticals Inc. Eli Lilly and Co. ND UK approval of Prozac for premenstrual dysphoric disorder (PMDD) Interneuron received an undisclosed payment from Lilly based on the regutory approval in the UK of Prozac for the treatment of PMDD; the payment was made under a June 1997 license agreement between the companies, which provided Lilly with U.S. and global patent application rights covering the use of Prozac for the listed indication (10/20)
Introgen Therapeutics Inc. Rh(ne-Poulenc Rorer 6 Seventh and final milestone (ND) RPR paid $6M milestone in connection with collaboration dating to 10/94; companies have taken p53 gene therapy for cancer through Phase II testing and are planning Phase III trials (6/22)
Isis Pharmaceuticals Inc. Elan Corp. plc (Ireland) 27 Signing of a binding letter of agreement to form a new subsidiary of Isis to develop a platform technology for oral delivery of antisense drugs Elan will make a $27M equity investment in Isis, consisting of $15M of common stock purchased at premium to market and $12M of convertible exchangeable preferred stock; Elan will also receive warrants exercisable in 5 years and has right to convert preferred stock into either an ownership interest in Isis or in the new subsidiary (4/12)
Isis Pharmaceuticals Inc. CIBAVision Corp. 2.5 Marketing approval of Vitravene in the European Union Isis received a $2.5M milestone payment from CIBAVision in connection with CMA marketing approval of Vitravene in the European Union; under the terms of the companies' worldwide distribution agreement, CIBAVision has worldwide marketing rights to Vitravene (8/4)
Karo Bio AB (Sweden) Bristol-Myers Squibb Co. ND Development of lead compounds Karo Bio received an undisclosed payment from Bristol-Myers under an October 1997 research collaboration agreement for the development of lead compounds targeting thyroid hormone receptor beta (10/14)
Ligand Pharmaceuticals Inc. Wyeth-Ayerst Laboratories (subsidiary of American Home Products) ND Submission of IND for ERA923 Ligand submitted IND for ERA-923, a tissueselective estrogen receptor modulator for breastcancer treatment (3/1)
Ligand Pharmaceuticals Inc. Wyeth-Ayerst Laboratories (a division of American Home Products Corp.) ND Election to proceed with development of clinical candidate Ligand received an undisclosed milestone payment from Wyeth-Ayerst upon the company's election to proceed with preclinical development of the clinical candidate WAY160910, a nonsteroidal progesterone receptor antagonist; Ligand will receive additional milestone payments and royalties upon IND filing and marketing approval (9/21)
Ligand Pharmaceuticals Inc. Glaxo Wellcome plc (UK) 2 Advancement of two research compounds into exploratory development Ligand received two $1M payments from Glaxo as milestone payments based on Glaxo advancing two research compounds into exploratory development for the treatment of cardiovascular disease; additional milestones will be due if the compounds proceed further in development, including the acceptance by the FDA of an investigational new drug application (10/28)
Lynx Therapeutics Inc. BASF AG (Germany) 4.5 Achievement of technical milestones Lynx received a $4.5M payment from BASF after successful experiments using Lynx's Megasort and Massively Parallel Signature Sequencing technologies to extract differentially expressed genes from two different microbial samples (10/6)
Medarex Inc. Novartis AG (Switzerland) 1 Terms of license agreement Medarex received a $1M technology access fee under its global licensing arrangement with Novartis involving Medarex's HuMAb-Mouse technology; the fee was paid in the form of an equity purchase (11/11)
Millennium Pharmaceuticals Inc. Eli Lilly & Co. ND Delivery of validated target Millennium received an undisclosed milestone payment from Lilly upon Lilly's acceptance of a validated target for drug candidate screening for the treatment of prostate cancer (12/20)
Millennium Pharmaceuticals Inc. Wyeth-Ayerst Research (a division of American Home Products Corp.) ND Delivery of validated target Millennium received an undisclosed milestone payment from Wyeth-Ayerst upon Ayerst's acceptance of a validated target for high-throughput screening (12/13)
Multiple Peptide Systems Elan Corp. plc (Ireland) 5 Equity investment made separately from, but at the same time as, formation of joint venture Elan made $5M equity investment in MPS (4/7)
Nabi ND ND Sale of antibody collection centers Nabi received cash payment; amount ND (4/23)
NeoPharm Inc. Pharmacia & Upjohn 8 Transfer of investigational new drug applications (INDs) Under the terms of their Feb. 1999 licensing agreement, NeoPharm sold 0.5M shares of its stock to Pharmacia & Upjohn at $17.67 per share for an equity investment total of $8M; the stock sale provision of the agreement was triggered by the transfer of the INDs for NeoPharm's two anticancer agents, Liposomal Encapsulated Paclitaxel and Liposomal Encapsulated Doxorubicin (8/2)
Neurocrine Biosciences Inc. Wyeth-Ayerst Laboratories (division of American Home Products Corp.) 0.75 Fundamental discovery under research collaboration Neurocrine received a $750,000 milestone payment for a fundamental discovery in EAATs (excitatory amino acid transporters) neurotransmitter transporter biology (8/3)
Nexell Therapeutics Inc. (formerly Vimrx Pharmaceuticals Inc.) Baxter International Inc. 20 - Baxter will provide either a $20M line of credit or help support and complete a larger private placement financing; transaction is part of a restructuring of 12/97 agreement creating Nexell to commercialize Baxter's Isolex stemcell selection system (5/10)
Oxford Assymetry International plc (UK) Ontogeny Inc. ND Achievement of collaborative milestone Oxford received an undisclosed payment from Ontogeny as a result of achieving a target biological activity in a lead optimization program (12/14)
Quark Biotech Inc. Mitsubishi-Tokyo Pharmaceuticals Inc. (Japan) ND Terms of collaborative agreement Quark received an undisclosed milestone payment under an existing collaborative research and license agreement (12/15)
Ribozyme Pharmaceuticals Inc. Eli Lilly and Co. 7.5 - Lilly purchased $7.5M worth of Ribozyme stock under the terms of 3/99 collaboration on ribozymes for treatment of hepatitis C virus (5/10)
SkyePharma plc (UK) Novartis Pharma AG (Switzerland) ND Commencement of clinical trials SkyePharma received an undisclosed payment from Novartis upon the news that a new formulation of Foradil, using SkyePharma's multi-dose dry powder inhaler, began clinical trials (10/13)
Structural Bioinformatics Inc. Yamanouchi Pharmaceutical Co. Ltd. (Japan) ND Provided smallmolecule leads Structural Bioinformatics used protein modeling and DynaPharm technologies to find small-molecule leads starting from the gene sequence of the protein target (3/8)
Transkaryotic Therapies Inc. Aventis (a division of Aventis S.A.) 2.5 Filing of investigational new drug application (IND) Transkaryotic Therapies received a $2.5M payment from Aventis upon filing an IND with the FDA to commence Phase I studies of a gene-activated protein product (12/21)
Unigene Laboratories Inc. Parke-Davis (division of Warner-Lambert Co.) 2.5 Conclusion of pilot study The companies signed a licensing agreement on Unigene's oral calcitonin for treating osteoporosis in 7/97; Unigene received a $2.5M milestone associated with the conclusion of a pilot human study (2/26)
Unigene Laboratories Inc. Warner-Lambert Co. 2.5 Conclusion of final pilot human study Unigene received a $2.5M milestone payment from Warner in connection with the conclusion of the final pilot human study prior to initiating Phase I studies with an oral calcitonin formulation (8/19)
Unigene Laboratories Inc. Warner-Lambert Co. 0.5 Identification of clinical trial candidate Unigene received a $0.5M payment upon the identification of an oral calcitonin formulation that will be used in a Phase I study; Unigene will receive the balance of the $4.5M milestone upon initiation of the Phase I study (9/22)
Vical Inc. Merck & Co. Inc. 2 Terms of license agreement Vical received a $2M payment from Merck in accordance with the companies' 1997 license agreement; the payment extends Merck's exclusive worldwide rights to use Vical's naked DNA non-viral gene delivery technology to develop and market therapeutic vaccines against the HIV and hepatitis B viruses (11/3)
V.I. Technologies Inc. Pall Corp. 3 Commencement of Phase I patient enrollment V.I. Technologies received a $3M payment from Pall as a result of enrolling the first patient in a Phase I trial of the company's Inactine viral inactivation technology (12/6)
Vivus Inc. AstraZeneca Group plc (UK) 2 Marketing approval of Muse (alprostadil) in Spain Vivus received a $2M milestone payment from AstraZeneca in connection with receiving a marketing license in Spain for Muse (alprostadil), a treatment for erectile dysfunction (8/27)
Xoma Ltd. Genentech Inc. 2 Completion of Phase II trial The companies entered an agreement in 4/96 to jointly develop Genentech's anti-CD11a humanized monoclonal antibody (a.k.a. hu1124) for treating psoriasis and organ transplant rejection; Xoma completed a Phase II trial in the psoriasis indication, triggering a $2M milestone payment (1/7)